• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Inhibition of Fatty Acid Synthase (FAS): A New Drug for Breast Cancer Chemoprevention
【24h】

Inhibition of Fatty Acid Synthase (FAS): A New Drug for Breast Cancer Chemoprevention

机译：抑制脂肪酸合成酶（Fas）：一种新的乳腺癌化学预防药物

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Fatty acid synthase (FAS) has shown promise as a new target for breast cancer therapy. FAS is the primary enzyme responsible for the de novo synthesis of fatty acid and is highly expressed in most common human cancers, including breast, colorectal, prostate, ovary, and lung. Moreover, high levels of FAS have been found in cancer precursor lesions of the breast, prostate, and colon. In contrast, dietary fat down-regulates FAS and fatty acid synthesis in most normal tissues. To test the effect of FAS inhibition in cancer, we have developed a novel, chemically stable, small molecule FAS inhibitor, C75, that induces apoptosis in human breast cancer cells in vitro and in vivo. C75 has shown significant anti-tumor effect against MCF-7 human breast cancer xenografts in athymic mice. In light of these data, we have demonstrated that inhibition of FAS delays or eliminates mammary cancer in the neu-N transgenic mouse mammary cancer model. Moreover, treatment reduced the expression of genes known to be involved in neu signal transduction.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号